Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200319 | 0.90 | TSHR (0.49) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL22199660 | 0.87 | POLB (0.49) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20049915 | 0.86 | POLB (0.49) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL23119558 | 0.84 | POLB (0.47) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20340664 | 0.84 | POLB (0.47) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL8379974 | 0.83 | L3MBTL1 (0.48) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL19645192 | 0.83 | POLB (0.48) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20374788 | 0.80 | POLB (0.46) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL4193078 | 0.80 | L3MBTL1 (0.46) | POLBHPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20112946 | 0.79 | RAB9A (0.56) | POLBHPGDHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988507-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190322704-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988507-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | POLB 2800/4885HPGD 1110/4885HTT 4618/4885 |
| US-20190322704-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | POLB 2800/4885HPGD 1110/4885HTT 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.